{
    "nct_id": "NCT03428217",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)",
    "inclusion_criteria": "1. Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component\n2. Adult patients\n3. Karnofsky Performance Score (KPS) â‰¥ 70%\n4. Measurable Disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\n5. 1-2 lines of prior therapy for advanced or metastatic renal cell carcinoma (RCC) including one anti-angiogenic therapy (any vascular endothelial growth factor [VEGF] pathway-targeted agent used either as monotherapy or as a component of a combination regimen) OR the combination regimen of nivolumab + ipilimumab\n6. Adequate hepatic, renal, cardiac and hematologic function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with cabozantinib (or other mesenchymal-epithelial transition [MET] inhibitor) or CB-839\n2. Receipt of other anticancer therapy within 2-6 weeks, depending on the treatment\n3. Untreated or active brain metastases or central nervous system cancer, as defined per protocol\n4. Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug\n5. Known active infection with human immunodeficiency virus (HIV), Hepatitis B or C virus\n6. Inability to discontinue proton-pump-inhibitor use before randomization\n7. Patients who are pregnant or lactating",
    "miscellaneous_criteria": ""
}